Neutral On BiogenDaily Markets (blog)Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen's pipeline also has candidates for other ailmen…
Neutral on BiogenZacks.comOther interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs (ABT), and PEGylated interferon. Biogen's pipeline also has candidates for other ailments like amyotrop…
Biogen Idec prepares for multiple launches in coming yearsThe Pharma Letter… which will both have data readouts this year. o Delivering the data readout from the first Phase III trial of dexpramipexole in ALS by year-end. o Continuing to advance the …
PDL BioPharma's CEO Presents at 30th Annual JP Morgan Healthcare Conference …Seeking AlphaDaclizumab is a product which is now jointly owned between Abbott and Biogen Idec for multiple sclerosis. They reported some very nice data from one of thei…
Biogen Idec presenta sus prioridades estratégicas para 2012 en el 30º Congreso …Business Wire (Comunicado de prensa)Seguir avanzando el programa de Fase 3 de daclizumab sobre EM. La creación de equipos científicos de tipo mundial en sus áreas te…
Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan …EON: Enhanced Online News (press release)Continuing to advance the daclizumab Phase 3 program in MS. Building world-class scientific teams in its core therapeutic areas. Advan…
Biogen Idec presenta sus prioridades estratégicas para 2012 en el 30º Congreso …ecodiarioSeguir avanzando el programa de Fase 3 de daclizumab sobre EM. La creación de equipos científicos de tipo mundial en sus áreas terapéuticas principales. Av…
Biogen Idec presenta sus prioridades estratégicas para 2012 en el 30º Congreso …elEconomista.esSeguir avanzando el programa de Fase 3 de daclizumab sobre EM. La creación de equipos científicos de tipo mundial en sus áreas terapéuticas principal…
Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan …Business Wire (press release)Continuing to advance the daclizumab Phase 3 program in MS. Building world-class scientific teams in its core therapeutic areas. Advancing the com…
Biogen Idec stellt auf der 30. Annual J.P. Morgan Healthcare Conference …Business Wire (Pressemitteilung)Weitere Fortentwicklung des Programms Phase 3 mit Daclizumab bei MS. Bildung von Wissenschaftlerteams von Weltklasse in den therapeutischen Kernb…